Al­lo­gene blue­prints a new man­u­fac­tur­ing com­plex for next-gen CAR-T; In­ovio spins out neoanti­gen up­start with $10.5M A round

→ David Chang and Arie Bellde­grun are back in the busi­ness of build­ing man­u­fac­tur­ing fa­cil­i­ties. Their start­up Al­lo­gene $AL­LO has inked a deal to build a state-of-the-art cell ther­a­py man­u­fac­tur­ing site in Newark, CA. That may sound a bit mun­dane in the world of drug de­vel­op­ment, but it’s crit­i­cal to the com­pa­ny’s longterm suc­cess — as the two founders learned start­ing Kite.

One of the best fund­ed biotech star­tups in the class of 2018, Al­lo­gene is adding a 118,000-square-foot fa­cil­i­ty at the Gate­way 84 Sil­i­con Val­ley ad­vanced man­u­fac­tur­ing cam­pus. The com­pa­ny al­so plans to con­tin­ue us­ing a CMO for added pro­duc­tion of their off-the-shelf CAR-Ts, which they be­lieve is on track to sup­plant the two pi­o­neer­ing per­son­al­ized CAR-Ts on the mar­ket.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER